4 ms·
A number of PARP inhibitors have been recently approved by the FDA as maintenance therapy for ovarian cancer (Olaparib, for example). Since the standard course
by DrAwdeOccarim 7y ago
A number of PARP inhibitors have been recently approved by the FDA as maintenance therapy for ovarian cancer (Olaparib, for example). Since the standard course of treatment for these patients is months to years of treatment, there may be a real-world test of this discovery and the impact of decreased poly ADP ribose on atherosclerosis. Someone should send this article to AZ and Merck so they can follow up with these patients.